Progress in the treatment of childhood brain tumors: No room for complacency - Commentary

Pediatric Hematology and Oncology

Volumn 24, Issue 1, 2007, Pages 79-84

  Finlay, Jonathan L ^a   Erdreich Epstein, Anat ^a   Packer, Roger J ^b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; METHOTREXATE; MYELOABLATIVE AGENT;

AKINETIC MUTISM; ASTROCYTOMA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BRAIN TUMOR; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; COGNITION; CRANIOPHARYNGIOMA; DEVELOPED COUNTRY; DISEASE FREE SURVIVAL; EPENDYMOMA; HIGH RISK PATIENT; HUMAN; INCIDENCE; MEDULLOBLASTOMA; NEUROSURGERY; NOTE; OTOTOXICITY; POSTERIOR CRANIAL FOSSA SYNDROME; SURVIVAL RATE; SYSTEMIC THERAPY; TREATMENT INDICATION; UNITED STATES;

BRAIN NEOPLASMS; CEREBELLAR NEOPLASMS; CHILD; HUMANS; MEDULLOBLASTOMA;

EID: 33845249478     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010601001073     Document Type: Note

References (15)

1. Jemal A, Clegg LX, Ward S, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004;101:3-27.
2. Pollack IF, Polinko P, Albright AL. Mutism and pseudobulbar symptoms after resection of posterior fossa tumors in children: incidence and pathophysiology. Neurosurgery. 1995;37:885-893.
3. Thomas PRM, Deutsch M, Keppner JL, et al. Low stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol. 2000;18:3004-3011.
4. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly-diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24:4202-4206.
5. Gilbertson RJ. Medulloblastoma: signaling a change in treatment. Lancet Oncol. 1998;5:209-218.
6. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993;328:1725-1731.
7. Rutkowski S, Bode U, Deinlein F, et al. Treatment of Early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352:978-986.
8. Mason WP, Grovas A, Halpern S, et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol. 1998;16:210-221.
9. Sands S, van Gorp W, Finlay JL. Pilot neuropsychological findings from a treatment regimen consisting of intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. Child's Nerv Syst. 1998;14:587-589.
10. Chi SN, Gardner S, Levy AS, et al. Newly diagnosed high-risk malignant brain tumors with leptomeningeal dissemination in young children: response to "Head Start" induction chemotherapy intensified with high-dose methotrexate. J Clin Oncol. 2004;22:4881-4887.
11. Gilbertson RJ and Gajjar A. Molecular biology of medulloblastomas: will it ever make a difference to clinical management? J Neuro-oncol. 2005;75:273-278.
12. Warren KE. Molecularly targeted therapy for pediatric brain tumors. J Neuro-oncol. 2005;75:335-343.
13. Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24:1924-1931.
14. Kieran MW. Anti-angiogenesis therapy in pediatric neuro-oncology. J Neuro-oncol. 2005;75:327-334.
15. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A. 2003;100:12917-2922.